ReviewEye (London, England)2020
A review of systemic medications that may modulate the risk of glaucoma.
Review in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- The Relevance of Arterial Blood Pressure in the Management of Glaucoma Progression: A Systematic Review.American journal of hypertension · 2024Pooled it
- Serum Lipids and Glaucoma.Journal of atherosclerosis and thrombosis · 2026Article
- Monitoring and addressing anticholinergic-induced ocular adverse effects associated with psychotropic medication.The mental health clinician · 2026Article
- Systemic Medications as Triggers of Acute Angle-Closure Glaucoma: A Narrative Review.Journal of clinical medicine · 2026Review
- Statin Use and Primary Open-Angle Glaucoma Severity in Patients of African Ancestry.Research square · 2026Article
- Review
- Systemic α₂-agonist use and lower hazard of glaucoma compared with β-blockers: a cohort study.BMJ open ophthalmology · 2026Observational
- Risk of Glaucoma Progression in Patients Using a Calcium Channel Blocker: A Propensity-Matched Cohort Study.Investigative ophthalmology & visual science · 2026Article
- Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us.Ophthalmology · 2025Article
- Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist.Ophthalmology · 2025Article
- The hidden ophthalmic dangers of steroids in COVID-19 treatment: a case report.Translational pediatrics · 2025Article
- A new minimally invasive glaucoma surgery namely trabeculotome tunneling trabeculoplasty for steroid-induced glaucoma: a case report.International journal of ophthalmology · 2025Article
- Mesenchymal Stem Cell-Derived Exosomes for Ocular Diseases: Therapeutic Mechanisms and Clinical Perspectives.International journal of nanomedicine · 2025Review
- Daily activities change is linked to acute angle closure occurrence in COVID-19 co-infected patients.BMC ophthalmology · 2024Article
- Change in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study.Investigative ophthalmology & visual science · 2024Observational
- Systemic Medications and Their Ocular Side Effects.Cureus · 2024Review
- Amlodipine increases risk of primary open-angle glaucoma.Clinical hypertension · 2024Article
- Molecular Mechanisms of Glaucoma Pathogenesis with Implications to Caveolin Adaptor Protein and Caveolin-Shp2 Axis.Aging and disease · 2024Review
- Apoptosis in glaucoma: A new direction for the treatment of glaucoma (Review).Molecular medicine reports · 2024Review
- Thermosensitive In Situ Gelling Poloxamers/Hyaluronic Acid Gels for Hydrocortisone Ocular Delivery.Gels (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
With increasing longevity, patients are developing more and more chronic diseases that require treatment with medications. Yet, it is not fully understood the extent by which these systemic medications affect ocular structures and whether they may increase or decrease the risk of sight-threatening ocular diseases. This review provides a summary of reported associations between different systemic medications and the risk of developing glaucoma or experiencing disease progression. Medication classes covered in this review that are known to or may modulate the risk of open-angle glaucoma include corticosteroids, beta blockers, calcium channel blockers, metformin, statins, selective serotonin reuptake inhibitors, bupropion, postmenopausal hormones, and cannabinoids. Medication classes addressed in this review that may increase the risk of angle closure glaucoma include anticholinergics, adrenergic agonists, certain classes of antidepressants, sulfonamides, and topiramate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.